company background image

Grown Rogue International CNSX:GRIN Stock Report

Last Price


Market Cap







21 May, 2022


Company Financials
GRIN fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health3/6

GRIN Stock Overview

Grown Rogue International Inc., through its subsidiaries, engages in growing and selling cannabis products in the United States.

Grown Rogue International Competitors













Price History & Performance

Summary of all time highs, changes and price drops for Grown Rogue International
Historical stock prices
Current Share PriceCA$0.07
52 Week HighCA$0.23
52 Week LowCA$0.065
1 Month Change-12.50%
3 Month Change-30.00%
1 Year Change-53.33%
3 Year Change-73.08%
5 Year Changen/a
Change since IPO-75.86%

Recent News & Updates

Nov 10
Here's Why Grown Rogue International (CSE:GRIN) Has A Meaningful Debt Burden

Here's Why Grown Rogue International (CSE:GRIN) Has A Meaningful Debt Burden

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

GRINCA PharmaceuticalsCA Market

Return vs Industry: GRIN exceeded the Canadian Pharmaceuticals industry which returned -63.2% over the past year.

Return vs Market: GRIN underperformed the Canadian Market which returned 4.6% over the past year.

Price Volatility

Is GRIN's price volatile compared to industry and market?
GRIN volatility
GRIN Average Weekly Movement14.0%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement9.9%
10% most volatile stocks in CA Market16.9%
10% least volatile stocks in CA Market4.4%

Stable Share Price: GRIN is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: GRIN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

n/an/aJ. Strickler

Grown Rogue International Inc., through its subsidiaries, engages in growing and selling cannabis products in the United States. It offers flower products, such as indicas, sativas, and hybrids; and edibles, vape cartridges, pre-rolls, or concentrates. The company sells its products through dispensaries.

Grown Rogue International Fundamentals Summary

How do Grown Rogue International's earnings and revenue compare to its market cap?
GRIN fundamental statistics
Market CapUS$9.30m
Earnings (TTM)-US$1.90m
Revenue (TTM)US$12.06m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GRIN income statement (TTM)
Cost of RevenueUS$3.79m
Gross ProfitUS$8.27m
Other ExpensesUS$10.17m

Last Reported Earnings

Jan 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.011
Gross Margin68.60%
Net Profit Margin-15.75%
Debt/Equity Ratio26.0%

How did GRIN perform over the long term?

See historical performance and comparison


Is Grown Rogue International undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: GRIN is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.

PE vs Market: GRIN is unprofitable, so we can't compare its PE Ratio to the Canadian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GRIN's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: GRIN is overvalued based on its PB Ratio (1.5x) compared to the CA Pharmaceuticals industry average (1.2x).

Future Growth

How is Grown Rogue International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Grown Rogue International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Grown Rogue International performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GRIN is currently unprofitable.

Growing Profit Margin: GRIN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: GRIN is unprofitable, but has reduced losses over the past 5 years at a rate of 23% per year.

Accelerating Growth: Unable to compare GRIN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GRIN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (134.7%).

Return on Equity

High ROE: GRIN has a negative Return on Equity (0.65%), as it is currently unprofitable.

Financial Health

How is Grown Rogue International's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GRIN's short term assets ($8.3M) exceed its short term liabilities ($4.9M).

Long Term Liabilities: GRIN's short term assets ($8.3M) exceed its long term liabilities ($2.7M).

Debt to Equity History and Analysis

Debt Level: GRIN's net debt to equity ratio (7.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GRIN's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GRIN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GRIN has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.5% each year.


What is Grown Rogue International current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GRIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GRIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GRIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GRIN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GRIN has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


J. Strickler (41 yo)





Mr. J. Obie Strickler serves as President, Chief Executive Officer and Chairman at Grown Rogue International Inc. He Co-Founded Grown Rogue International Inc. He is the Director of Grown Rogue Internationa...

CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether J.'s total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: GRIN's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Experienced Board: GRIN's board of directors are considered experienced (3.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: GRIN insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.

Top Shareholders

Company Information

Grown Rogue International Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Grown Rogue International Inc.
  • Ticker: GRIN
  • Exchange: CNSX
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$11.944m
  • Shares outstanding: 170.63m
  • Website:


  • Grown Rogue International Inc.
  • 550 Airport Road
  • Medford
  • Oregon
  • 97504
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Annual Earnings2021/10/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.